Cargando…

Comparative drug screening in NUT midline carcinoma

BACKGROUND: The NUT midline carcinoma (NMC) is a rare but fatal cancer for which systematic testing of therapy options has never been performed. METHODS: On the basis of disease biology, we compared the efficacy of the CDK9 inhibitor flavopiridol (FP) with a panel of anticancer agents in NMC cell li...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beesley, A H, Stirnweiss, A, Ferrari, E, Endersby, R, Howlett, M, Failes, T W, Arndt, G M, Charles, A K, Cole, C H, Kees, U R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3950881/ https://www.ncbi.nlm.nih.gov/pubmed/24518598 http://dx.doi.org/10.1038/bjc.2014.54

Ejemplares similares

Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma—an aggressive and fatal disease
por: Stirnweiss, Anja, et al.
Publicado: (2017)

A novel BRD4-NUT fusion in an undifferentiated sinonasal tumor highlights alternative splicing as a contributing oncogenic factor in NUT midline carcinoma
por: Stirnweiss, A, et al.
Publicado: (2015)

Sulphoxythiocarbamates modify cysteine residues in HSP90 causing degradation of client proteins and inhibition of cancer cell proliferation
por: Zhang, Y, et al.
Publicado: (2014)

Impact of mutant β-catenin on ABCB1 expression and therapy response in colon cancer cells
por: Stein, U, et al.
Publicado: (2012)

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
por: Goede, V, et al.
Publicado: (2010)

Interleukin-6 mediated upregulation of CYP1B1 and CYP2E1 in colorectal cancer involves DNA methylation, miR27b and STAT3
por: Patel, S A A, et al.
Publicado: (2014)

Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations
por: Bramley, M, et al.
Publicado: (2006)

Angiogenesis and vascular network of teratocarcinoma from embryonic stem cell transplant into seminiferous tubules
por: Silván, U, et al.
Publicado: (2009)

Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
por: Ioannou, N, et al.
Publicado: (2011)

Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer
por: Mochiki, E, et al.
Publicado: (2012)

Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia
por: Daayana, S, et al.
Publicado: (2010)

Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines
por: Zaremba, T, et al.
Publicado: (2009)

TCTP as a therapeutic target in melanoma treatment
por: Boia-Ferreira, M, et al.
Publicado: (2017)

Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer
por: Janssen, A, et al.
Publicado: (2017)

Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells
por: Ammerpohl, O, et al.
Publicado: (2007)

γ-Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate
por: Kim, S-E, et al.
Publicado: (2013)

Epigenetic silencing of miRNA-9 is associated with HES1 oncogenic activity and poor prognosis of medulloblastoma
por: Fiaschetti, G, et al.
Publicado: (2014)

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
por: Bray, J, et al.
Publicado: (2010)

VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008)

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
por: Michlmayr, A, et al.
Publicado: (2010)

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
por: Schiffmann, L M, et al.
Publicado: (2017)

Enzastaurin has anti-tumour effects in lung cancers with overexpressed JAK pathway molecules
por: Shimokawa, T, et al.
Publicado: (2012)

Transport kinetics of four- and six-coordinate platinum compounds in the multicell layer tumour model
por: Modok, S, et al.
Publicado: (2007)

Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach
por: Zeisberger, S M, et al.
Publicado: (2006)

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients
por: Pieck, A C, et al.
Publicado: (2008)

Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival
por: Kim, J-S, et al.
Publicado: (2009)

Phase I and pharmacological study of the broad-spectrum tyrosine kinase inhibitor JNJ-26483327 in patients with advanced solid tumours
por: Konings, I R H M, et al.
Publicado: (2010)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

Combining clinicopathological predictors and molecular biomarkers in the oncogenic K-RAS/Ki67/HIF-1α pathway to predict survival in resectable pancreatic cancer
por: Qin, R, et al.
Publicado: (2015)

Defects in muscarinic receptor-coupled signal transduction in isolated parotid gland cells after in vivo irradiation: evidence for a non-DNA target of radiation
por: Coppes, R P, et al.
Publicado: (2005)

The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting
por: Kailayangiri, S, et al.
Publicado: (2012)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos
por: Farnoushi, Y, et al.
Publicado: (2011)

Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels
por: Giovannetti, E, et al.
Publicado: (2007)

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008)

Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance
por: Kaliszczak, M, et al.
Publicado: (2013)

Treatment decisions and survival for people with small-cell lung cancer
por: Powell, H A, et al.
Publicado: (2014)

Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin
por: Graat, H C A, et al.
Publicado: (2006)

Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
por: van Leeuwen, R W F, et al.
Publicado: (2013)

Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse
por: Shaw, P H S, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_bo1rugoqoh7fi8v6ak6nle06cs